Abiopharma

🔍 Steinhart Richard I (Executive)

Company: BioXcel Therapeutics, Inc. (BTAI)

Report Date: 2025-12-14

Detailed Transactions and Holdings:

• Acquired 33 shares of Common Stock (Direct)
  Date: 2025-12-14 | Code: M | equity_swap_involved: 0 | shares_owned_after: 6,542.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 35 shares of Common Stock (Direct)
  Date: 2025-12-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 6,577.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 33 shares of Restricted Stock Units (Derivative)
  Date: 2025-12-14 | Code: M | equity_swap_involved: 0 | shares_owned_after: 130.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Sold 35 shares of Restricted Stock Units (Derivative)
  Date: 2025-12-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 282.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
• F2: On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
• F3: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.